WO2001068708A3 - ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a) - Google Patents

ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a) Download PDF

Info

Publication number
WO2001068708A3
WO2001068708A3 PCT/EP2001/004716 EP0104716W WO0168708A3 WO 2001068708 A3 WO2001068708 A3 WO 2001068708A3 EP 0104716 W EP0104716 W EP 0104716W WO 0168708 A3 WO0168708 A3 WO 0168708A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
human
specific antibodies
fap
humanized
Prior art date
Application number
PCT/EP2001/004716
Other languages
English (en)
Other versions
WO2001068708A9 (fr
WO2001068708A2 (fr
Inventor
John-Edward Park
Pilar Garin-Chesa
Klaus Pfizenmaier
Dieter Moosmayer
Michael Mersmann
Alexej Schmidt
Original Assignee
Boehringer Ingelheim Pharma
Park John Edward
Garin Chesa Pilar
Klaus Pfizenmaier
Dieter Moosmayer
Michael Mersmann
Alexej Schmidt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10013286A external-priority patent/DE10013286A1/de
Priority claimed from GB0022216A external-priority patent/GB0022216D0/en
Application filed by Boehringer Ingelheim Pharma, Park John Edward, Garin Chesa Pilar, Klaus Pfizenmaier, Dieter Moosmayer, Michael Mersmann, Alexej Schmidt filed Critical Boehringer Ingelheim Pharma
Priority to JP2001567798A priority Critical patent/JP2003530092A/ja
Priority to AU2001256325A priority patent/AU2001256325A1/en
Priority to CA002401252A priority patent/CA2401252A1/fr
Priority to EP01929604A priority patent/EP1268550A2/fr
Publication of WO2001068708A2 publication Critical patent/WO2001068708A2/fr
Publication of WO2001068708A3 publication Critical patent/WO2001068708A3/fr
Publication of WO2001068708A9 publication Critical patent/WO2001068708A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des protéines anticorps qui se lient spécifiquement à la protéine alpha activatrice de fibroblaste (FAPα). Elle concerne aussi l'utilisation des ces anticorps aux fins de diagnostic et de traitement thérapeutique, ainsi que des procédés de préparation de ces anticorps.
PCT/EP2001/004716 2000-03-17 2001-03-16 ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a) WO2001068708A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001567798A JP2003530092A (ja) 2000-03-17 2001-03-16 ヒトＦＡＰ−α−特異抗体
AU2001256325A AU2001256325A1 (en) 2000-03-17 2001-03-16 Human and humanized fap-alpha-specific antibodies
CA002401252A CA2401252A1 (fr) 2000-03-17 2001-03-16 Anticorps humains specifiques de fap-.alpha.
EP01929604A EP1268550A2 (fr) 2000-03-17 2001-03-16 Anticorps humains specifiques de fap-alpha

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10013286A DE10013286A1 (de) 2000-03-17 2000-03-17 Humane FAP-alpha-spezifische Antikörper
DE10013286.3 2000-03-17
GB0022216.6 2000-09-11
GB0022216A GB0022216D0 (en) 2000-09-11 2000-09-11 Human FAP-a-specific antibodies for use in cancer therapy

Publications (3)

Publication Number Publication Date
WO2001068708A2 WO2001068708A2 (fr) 2001-09-20
WO2001068708A3 true WO2001068708A3 (fr) 2002-05-02
WO2001068708A9 WO2001068708A9 (fr) 2003-05-22

Family

ID=26004887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/004716 WO2001068708A2 (fr) 2000-03-17 2001-03-16 ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)

Country Status (5)

Country Link
EP (1) EP1268550A2 (fr)
JP (1) JP2003530092A (fr)
AU (1) AU2001256325A1 (fr)
CA (1) CA2401252A1 (fr)
WO (1) WO2001068708A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
EP1806365A1 (fr) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
WO2011069019A2 (fr) 2009-12-02 2011-06-09 David Ho Minobodies j591 et cys-diabodies pour le ciblage de l'antigène membranaire spécifique de la prostate humaine (psma), et procédés d'utilisation
MA34519B1 (fr) 2010-08-13 2013-09-02 Roche Glycart Ag Anticorps anti-fap et procédés d'utilisation
EP2673294B1 (fr) 2011-02-10 2016-04-27 Roche Glycart AG Polypeptides d'interleukine-2 mutants
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014167083A1 (fr) 2013-04-12 2014-10-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour prédire le risque de développer une néoplasie du côlon
GB201402006D0 (en) * 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
KR20180050321A (ko) 2015-08-07 2018-05-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
UA125962C2 (uk) 2015-10-02 2022-07-20 Ф. Хоффманн-Ля Рош Аг Біспецифічна антигензв'язуюча молекула до ox40 та фібробласт-активуючого білка (fap)
BR112019000015A2 (pt) 2016-06-30 2019-04-24 Oncorus, Inc. distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3555627B1 (fr) 2016-12-14 2023-11-22 Purdue Research Foundation Imagerie et thérapie ciblées par une protéine d'activation des fibroblastes (fap)
WO2018129497A1 (fr) 2017-01-09 2018-07-12 Bioxcel Therapeutics, Inc. Procédés prédictifs et diagnostiques pour le cancer de la prostate
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
CA3145872A1 (fr) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Composes comprenant un ligand de proteine d'activation des fibroblastes et leur utilisation
EP3763726A1 (fr) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation de fibroblastes et leur utilisation
AU2020310538A1 (en) 2019-07-08 2022-01-27 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
AU2021276332A1 (en) 2020-05-19 2022-11-17 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2022148843A1 (fr) 2021-01-07 2022-07-14 3B Pharmaceuticals Gmbh Composés comprenant un ligand de protéine d'activation des fibroblastes et leur utilisation
EP4050018A1 (fr) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation de fibroblastes et leur utilisation
WO2023125796A1 (fr) * 2021-12-30 2023-07-06 Concept To Medicine Biotech Co., Ltd. Anticorps humains contre fap-alpha
WO2024074727A1 (fr) 2022-10-07 2024-04-11 Genethon Immunothérapie cellulaire par car-t anti-fap pour traiter des myopathies squelettiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029233A1 (fr) * 1994-04-20 1995-11-02 Ludwig Institute For Cancer Research MOLECULE ISOLEE D'ACIDE NUCLEIQUE CODANT POUR UNE PROTEINE α D'ACTIVATION DE FIBROBLASTE ET UTILISATIONS
WO1999057151A2 (fr) * 1998-04-30 1999-11-11 Boehringer Ingelheim International Gmbh Anticorps alpha specifique fap a aptitude a la production amelioree

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029233A1 (fr) * 1994-04-20 1995-11-02 Ludwig Institute For Cancer Research MOLECULE ISOLEE D'ACIDE NUCLEIQUE CODANT POUR UNE PROTEINE α D'ACTIVATION DE FIBROBLASTE ET UTILISATIONS
WO1999057151A2 (fr) * 1998-04-30 1999-11-11 Boehringer Ingelheim International Gmbh Anticorps alpha specifique fap a aptitude a la production amelioree

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BREITLING F ET AL: "A SURFACE EXPRESSION VECTOR FOR ANTIBODY SCREENING", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 104, 1991, pages 147 - 153, XP002046118, ISSN: 0378-1119 *
RADER CHRISTOPH ET AL: "A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 15, 21 July 1998 (1998-07-21), July 21, 1998, pages 8910 - 8915, XP002182776, ISSN: 0027-8424 *
RETTIG ET AL: "fibroblast activation protein: purification, epitope mapping and induction by growth factors", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 58, August 1994 (1994-08-01), pages 385 - 392, XP002114043, ISSN: 0020-7136 *
RIPPMANN JOERG F ET AL: "Procaryotic expression of single-chain variable-fragment (scFv) antibodies: Secretion in L-form cells of Proteus mirabilis leads to active product and overcomes the limitations of periplasmic expression in Escherichia coli.", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 64, no. 12, December 1998 (1998-12-01), pages 4862 - 4869, XP002182777, ISSN: 0099-2240 *
SCHMIDT ALEXEJ ET AL: "Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 268, no. 6, March 2001 (2001-03-01), pages 1730 - 1738, XP001019035, ISSN: 0014-2956 *
WATZKA H ET AL: "Guided selection of antibody fragments specific for human interferon gamma receptor 1 from a human VH- and VL-gene repertoire", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 4, 1998, pages 279 - 291, XP004115267, ISSN: 1380-2933 *

Also Published As

Publication number Publication date
EP1268550A2 (fr) 2003-01-02
JP2003530092A (ja) 2003-10-14
AU2001256325A1 (en) 2001-09-24
WO2001068708A9 (fr) 2003-05-22
WO2001068708A2 (fr) 2001-09-20
CA2401252A1 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
IL203894A (en) Use of a polypeptide to prepare a drug to induce angiogenesis or liver regeneration
WO2003057134A3 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
PL378333A1 (pl) Sposoby profilaktyki i leczenia choroby Alzheimera (AD)
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
HUP0600688A3 (en) Methods of administering anti-tnf alpha antibodies
WO2005012493A3 (fr) Anticorps anti-cd19
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
WO2004039956A3 (fr) Compositions et methodes de traitement de maladies liees au systeme immunitaire
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
WO2004092215A3 (fr) Methodes therapeutiques utilisant des agents liants specifiques de l'angiopoietine-2 humaine
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2000078344A8 (fr) Peptides proteiniques du prion et utilisations associees
WO2001064877A3 (fr) Gene humain de la schizophrenie
DE60232862D1 (de) Rekombinantes pockenvirus für chimäre proteine des menschlichen immunschwächevirus
MY141459A (en) Recombinant anti-idiotypic antibodies
WO2004024072A3 (fr) Nouvelles compositions et methodes pour le traitement de maladies associees au systeme immunitaire
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
WO2001057219A3 (fr) Cytokines mammaliennes, leurs recepteurs, reactifs et procedes correspondants
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2001064876A3 (fr) Gene humain de la schizophrenie
WO2001040465A3 (fr) Compositions et procedes de traitement de maladies d'ordre immunologique
WO2003055440A8 (fr) Compositions et methodes de traitement de maladies d'origine immune
WO2006038101A3 (fr) Nouveaux anticorps et antigenes associes au cancer et leur utilisation dans le diagnostic du cancer
WO2001002429A3 (fr) Angiopoietine 6 et ses utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AU BG BR CA CN CO CZ EE HR HU ID IL IN JP KR LT LV MX NO NZ PL RO SG SI SK UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2401252

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001929604

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 567798

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/A/2002/009066

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2001929604

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/25-25/25, DRAWINGS, REPLACED BY NEW PAGES 1/25-25/25; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2001929604

Country of ref document: EP